This Website is a resource for information about SCILEX Pharmaceuticals and its products.
Collection on nonpersonal information
SCILEX may collect non-personally identifiable information about how you use this Website using analysis technologies. These analysis technologies may be provided by third parties. Information that might be collected using these technologies includes, for example, the pages you visit on this Website, the paths you take within this Website, and the length of time that you spend on this Website. We use this information in the aggregate in order to better understand how to improve the quality of this Website.
As is common among Internet site operators, the operator of this Website maintains Web server logs. Web servers automatically identify your computer by its IP address and collect that information in its Web server logs. An IP address is a number that is automatically assigned to your computer by your Internet service provider whenever you log onto the World Wide Web or “surf” the Internet. The SCILEX Web server logs collect statistical data that are generated by your computer when it visits this Website, such as the type of Web browser and operating system used to access the Website, the domain name of your Internet service provider, the date and time you access this Website, and the pages you visit. This Website uses this non-personally identifying Web server log information for a variety of purposes. Some of these purposes include: system administration; examination of overall traffic trends on this Website; troubleshooting; and the collection of broad demographic information about users of this Website. No personally identifiable information is contained in these Web server logs. The log files may be purged periodically, in our discretion, to maximize space on the server.
Use of information
We may collect personally identifying information that you affirmatively provide to us, including, without limitation, your name, address, telephone number, and/or e-mail address and, if you are a physician, your specialty and certain generic patient and practice information.
From time to time, we may use this information to better understand your needs and how we can improve our products and services. When you voluntarily give us your personal contact information, we may use this information to contact you directly.
We may also disclose the aggregate statistical data that we collect to third parties in order to allow them to measure the effectiveness of our programs and advertisements.
Comments, e-mails, suggestions, or other communications sent by you to us are deemed to be nonconfidential (except with regard to personally identifying information included therein), and we are free to use or distribute them in any way without compensation to the author, sender, or any other party.
We might also merge the information collected through offline sources with data collected through our Website into a database.
Security of data stored by SCILEX
SCILEX has security measures in place to protect the loss, misuse, and alteration of information under our control. While we make reasonable efforts to ensure the integrity and security of our network and systems, we cannot guarantee that our security measures will prevent third parties from illegally obtaining this information. You should consider any communication that you transmit to SCILEX (such as personally identifying or other data, questions, answers, comments, or suggestions) as nonconfidential and agree that SCILEX shall not be liable or responsible if any information about you is intercepted and used by an unintended recipient.
Collection of personally identifying information from or about children
This Website is not intended or designed to attract children under the age of 18. SCILEX uses reasonable efforts not to collect, use, or disclose personally identifiable information from children under the age of 18.
We do not disclose your personal information to third parties for the third parties’ direct marketing purposes, as governed by California Civil Code 1798.83.
Access or correction of your personally identifying information; opt out from receiving communications
You may always contact us to remove or update personally identifiable information from our database. To request a copy of your personally identifiable information stored by SCILEX, please send an e-mail containing your request to email@example.com. You must provide your full name, e-mail address, and any other information reasonably requested by SCILEX. You may then correct or delete such information using the procedures specified in the e-mail message. In addition, if you no longer wish to receive communications from us, you may opt out at any time by notifying us at firstname.lastname@example.org.
© 2018 SCILEX Pharmaceuticals Inc.
All rights reserved.
Important Safety Information
ZTLIDO is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
Warnings and Precautions
Accidental exposure can occur even after a ZTLIDO patch has been used. Small children or pets could suffer serious adverse effects from chewing or ingesting a new or used ZTLIDO patch. Store and dispose of patches properly and keep out of reach of children and pets.
Excessive dosing or overexposure to lidocaine can occur. Longer duration of application, application of more than the recommended number of patches, smaller patients, or impaired elimination may all contribute to increased blood concentration levels of lidocaine. If lidocaine overdose is suspected, check drug blood concentration. Management of overdose includes close monitoring, supportive care, and symptomatic treatment.
Cases of methemoglobinemia have been reported with local anesthetic use, although patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, or concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. Signs and symptoms include cyanotic skin discoloration and/or abnormal coloration of the blood and may occur immediately or may be delayed after exposure. Methemoglobin levels may continue to rise leading to more serious central nervous system and cardiovascular adverse effects. Discontinue ZTLIDO and any other oxidizing agents. Depending on severity of the symptoms, patients may respond to supportive care or may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.
Application site reactions can occur during or immediately after treatment with ZTLIDO. This may include development of blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. Inform patients of these potential reactions and that severe skin irritation may occur with ZTLIDO if applied for a longer period than instructed.
Hypersensitivity cross-reactions may be possible for patients allergic to PABA derivatives. Manage hypersensitivity reactions by conventional means.
Eye exposure with ZTLIDO should be avoided. If eye contact occurs, immediately wash out the eye with water or saline and protect the eye (eg, eye glasses/eye wear) until sensation returns.
Side effects of ZTLIDO include application site reactions such as, irritation, erythema, and pruritus. These are not all of the adverse reactions that may occur. Please see full Prescribing Information for more information.
Use in Specific Populations
Use of ZTLIDO during lactation should be used with caution as lidocaine is excreted into breast milk. The limited human data with lidocaine in pregnant women are not sufficient to inform drug-associated risk for major birth defects and miscarriage.
To report SUSPECTED ADVERSE REACTIONS, contact SCILEX Pharmaceuticals Inc. at 1-866-SCILEX3 or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information.
Important Safety Information
ZTLIDO is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.Read More